

May 30, 2019



BioSig Technologies to Present at the 9th Annual LD Micro Invitational

Santa Monica, CA, May 30, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical technology company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that it will be presenting at the 9th Annual LD Micro Invitational, which is taking place at Luxe Sunset Hotel in Bel-Air, California on June 4-5, 2019. BioSig will be presenting on June 4 at 1:30pm (PST) in Track 1.

Mr. Kenneth Londoner, Chairman & CEO of BioSig Technologies, Inc., will do a presentation on the Company's recent progress, including successful clinical experience at the [Texas Cardiac Arrhythmia Institute](#) in Austin, TX, [Greenville Memorial Hospital](#) in Greenville, SC and [Indiana University School of Medicine](#), BioSig's first participation in the [Heart Rhythm Society's 40th Annual Scientific Sessions](#) on May 8-11, 2019 at Moscone Center in San Francisco, CA and recent additions to the Company's Board of Directors and Advisory Board. Mr. Londoner will also discuss the Company's progress with the [global IP strategy](#). To schedule a one-on-one meeting with BioSig, please contact Natasha Drapeau, EVP at ndrapeau@biosigtech.com.

About LD Micro

LD Micro was founded in 2006 with the purpose of being an independent newsletter resource in the microcap space. It has since transformed into several influential conferences annually (Invitational, Summit, and Main Event).

In 2015, LD Micro launched ldmicro.com as a portal to provide exclusive intraday information on the entire sector, including the first pure microcap index (LDMi) which covers stocks in North America with market capitalizations between \$50-\$300m.

About BioSig Technologies

BioSig Technologies is a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace (www.biosig.com). Led by a proven management team and a veteran Board of Directors, BioSig Technologies is preparing to commercialize its PURE EP™ System. The technology has been developed to address an unmet need in a large and growing market.

The Company's first product, PURE EP™ System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. The system is indicated for use under the supervision of licensed healthcare practitioners who are responsible for interpreting the data. This novel cardiac signal acquisition and display system is engineered to assist electrophysiologists in clinical decision-making during electrophysiology procedures

in patients with abnormal heart rates and rhythms. BioSig's ultimate goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and received FDA 510(k) clearance for the PURE EP™ System in August 2018.

Forward-looking Statements

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at <http://www.sec.gov>. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Natasha Drapeau
BioSig Technologies, Inc.
Executive Vice President
12424 Wilshire Blvd, Ste 745
Los Angeles, CA 90025
ndrapeau@biosigtech.com
310-620-9320



Source: BioSig Technologies, Inc.